Last
Update:
August 07, 2011
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader
6th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
-
POSTER
Use and safety of fosamprenavir in HIV-infected children in the European
Union: an ongoing
post-marketing surveillance study
A. Judd, L. E, L. Galli, T. Goetghebuer .et al
Poster
Abstract
- POSTER
A pilot study of the impact of switch to fosamprenavir and addition of
lovaza for treatment of hypertriglyceridemia in
HIV-infected subjects on antiretroviral therapy (ARVs)
F. Felizarta, A. Scarsella, H. Khanlou, et al
Poster
Abstract
- POSTER
Hepatic safety profile of fosamprenavir (FPV)-containing regimens in
HIV-1-infected subjects with or without hepatitis C
(HCV) or B (HBV) co-infection
B. Ha, B. Wine, M. Wisniewski,et al
Poster
Abstract
-
Pharmacokinetics,
cord blood concentrations, and tolerability of boosted fosamprenavir (FPV)
in pregnancy
M. Cespedes, S. Ford, G. Pakes, et al
Abstract
XVII International AIDS Conference
|
Switching to fosamprenavir (FPV) led to similar efficacy and
safety in HIV-1-infected subjects on
their first PI regimen:
a prospective, open-label, multicenter, randomized trial
(ESS100290)s
B. Young , E. Dejesus , A. Lamarca , et al
Abstract
4th IAS Conference on HIV Pathogenesis,
Treatment
and Prevention |
|
-
NEWS RELEASE
New head-to-head study comparing Lexiva and atazanavir show similar efficacy
and lipid changes
GSK
July 25, 2007
-
Long-term efficacy and safety of fosamprenavir (FPV) 1400mg once-daily (QD)
boosted by
ritonavir (RTV) 100 mg QD in previously antiretroviral-naïve HIV/AIDS
patients: phase I of
BOLD100 (COL109766)
Blick G, Greiger-Zanlungo P, Plasencia V, et al
Abstract
-
Lack of clinically relevant drug-drug interaction between ritonavir-boosted
GS-9137
(elvitegravir) and fosamprenavir/r
Ramanathan S, Mathias AA1, Shen G, et al
Abstract
-
Determination of body composition changes by total body DEXA after 48 weeks
of treatment with
once-daily fosamprenavir (FPV) boosted with two different doses of
ritonavir(r) plus abacavir
(ABC)/lamivudine(3TC): COL100758
Wohl D, Lancaster T, DeJesus E, et al
Abstract
-
Is fosamprenavir related rash associated with previous NNRTI
induced rash?
Huberman MJ, Laurido M, Cassetti I, et
al
Abstract
-
Safety and
Antiviral Activity of Fosamprenavir/Ritonavir Once Daily Regimens in
HIV-infected
Pediatric
Subjects Ages 2 to 18 Years (48-Week Interim Data, Study APV20003)
E Chadwick, W Borkowsky,
C Fortuny, et al
Abstract
-
Safety and
Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2-
to
18-Year-Old
Pediatric Subjects (Interim Data, Study APV29005)
C Cunningham, A
Freedman, S Read, et al
Abstract
-
Development of VircoTYPE HIV-1 Resistance Analysis including Clinical
Cutoffs for
Ritonavir-boosted
Atazanavir and Fosamprenavir
B Winters, J Montaner, R
Harrigan, et al
Abstract
-
Genotypic
Analysis of the Virological Response to Fosamprenavir/Ritonavir in Clinical
Trials:
Context and Triad
A G Marcelin, P Flandre,
JM Molina, et al
Abstract
XVI International AIDS Conference
|
Abstract
Impact of clinical and demographic factors on trough amprenavir
plasma concentrations in
HIV-infected patients treated with
ritonavir boosted fosamprenavir
Meynard J.-L., Michelon H., Poirier J.-M.,
et al
Abstract
|
6th
IAS Conference
Fosamprenavir Main Page
Main
New/Newsworthy
